FDA Fact Sheets Address Variants for Monoclonal Antibody Products

The U.S. Food and Drug Administration (FDA) recently released revised fact sheets for health care providers that include additional information on susceptibility of SARS-CoV-2 variants to each monoclonal antibody therapy available through an Emergency Use Authorization for COVID-19 treatment. The fact sheets contain details regarding specific variants and potential resistance. Download revised fact sheets for: BamlanivimabBamlanivimab and Etesevimab and REGEN-COV™ (Casirivimab with Imdevimab).